Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells $50,000.00 in Stock

Pro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot sold 1,000 shares of Pro-Dex stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $50.00, for a total transaction of $50,000.00. Following the completion of the sale, the director now owns 299,695 shares in the company, valued at $14,984,750. This trade represents a 0.33 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pro-Dex Stock Down 0.3 %

PDEX stock opened at $48.92 on Friday. The company has a market cap of $159.53 million, a price-to-earnings ratio of 24.34 and a beta of 0.68. Pro-Dex, Inc. has a twelve month low of $16.84 and a twelve month high of $59.60. The business has a 50 day moving average price of $39.78 and a two-hundred day moving average price of $39.11. The company has a quick ratio of 1.44, a current ratio of 2.58 and a debt-to-equity ratio of 0.33.

Pro-Dex (NASDAQ:PDEX) last released its earnings results on Thursday, January 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.23. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. Analysts anticipate that Pro-Dex, Inc. will post 2 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Northern Trust Corp lifted its stake in Pro-Dex by 14.1% in the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier’s stock valued at $1,672,000 after purchasing an additional 4,426 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Pro-Dex by 9.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,435 shares of the medical instruments supplier’s stock worth $819,000 after acquiring an additional 2,296 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Pro-Dex by 2.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier’s stock worth $740,000 after acquiring an additional 529 shares during the period. EAM Investors LLC bought a new stake in Pro-Dex in the 4th quarter valued at $1,047,000. Finally, O Shaughnessy Asset Management LLC acquired a new stake in Pro-Dex during the 4th quarter valued at $995,000. 15.28% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Pro-Dex from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.